Monopar Therapeutics (MNPR) Profit After Tax: 2017-2019
Historic Profit After Tax for Monopar Therapeutics (MNPR) over the last 3 years, with Dec 2019 value amounting to -$1.2 million.
- Monopar Therapeutics' Profit After Tax fell 35.53% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.2 million, marking a year-over-year decrease of 38.65%. This contributed to the annual value of -$4.2 million for FY2019, which is 30.88% down from last year.
- As of Q4 2019, Monopar Therapeutics' Profit After Tax stood at -$1.2 million, which was down 63.96% from -$736,080 recorded in Q3 2019.
- Over the past 5 years, Monopar Therapeutics' Profit After Tax peaked at -$372,915 during Q1 2017, and registered a low of -$14.9 million during Q3 2017.
- Moreover, its 3-year median value for Profit After Tax was -$806,214 (2018), whereas its average is -$2.0 million.
- The largest annual percentage gain for Monopar Therapeutics' Profit After Tax in the last 5 years was 95.70% (2018), contrasted with its biggest fall of 135.00% (2018).
- Over the past 3 years, Monopar Therapeutics' Profit After Tax (Quarterly) stood at -$713,583 in 2017, then fell by 24.79% to -$890,461 in 2018, then slumped by 35.53% to -$1.2 million in 2019.
- Its last three reported values are -$1.2 million in Q4 2019, -$736,080 for Q3 2019, and -$905,700 during Q2 2019.